Jiangxi Sanxin Medtec Co Ltd
Jiangxi Sanxin Medtec Co.,Ltd. engages in the research and development, manufacture, sale, and service of medical devices. The company offers infusion and cardiothoracic surgery products; and blood purification products, such as dialysate filter, dialysis indwelling needle, disposable biological protein glue dispenser, dialysis fluid filter, continuous blood purification pipeline and accessories,… Read more
Jiangxi Sanxin Medtec Co Ltd (300453) - Net Assets
Latest net assets as of September 2025: CN¥1.48 Billion CNY
Based on the latest financial reports, Jiangxi Sanxin Medtec Co Ltd (300453) has net assets worth CN¥1.48 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.31 Billion) and total liabilities (CN¥833.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.48 Billion |
| % of Total Assets | 63.93% |
| Annual Growth Rate | 20.67% |
| 5-Year Change | 66.66% |
| 10-Year Change | 164.85% |
| Growth Volatility | 27.21 |
Jiangxi Sanxin Medtec Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Jiangxi Sanxin Medtec Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jiangxi Sanxin Medtec Co Ltd (2011–2024)
The table below shows the annual net assets of Jiangxi Sanxin Medtec Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.41 Billion | +5.60% |
| 2023-12-31 | CN¥1.33 Billion | +15.45% |
| 2022-12-31 | CN¥1.16 Billion | +18.04% |
| 2021-12-31 | CN¥978.79 Million | +15.80% |
| 2020-12-31 | CN¥845.23 Million | +17.72% |
| 2019-12-31 | CN¥718.02 Million | +17.65% |
| 2018-12-31 | CN¥610.32 Million | +4.90% |
| 2017-12-31 | CN¥581.81 Million | +5.28% |
| 2016-12-31 | CN¥552.62 Million | +3.90% |
| 2015-12-31 | CN¥531.87 Million | +112.52% |
| 2014-12-31 | CN¥250.27 Million | +20.55% |
| 2013-12-31 | CN¥207.61 Million | +30.60% |
| 2012-12-31 | CN¥158.96 Million | +29.85% |
| 2011-12-31 | CN¥122.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangxi Sanxin Medtec Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2612.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥649.98 Million | 49.09% |
| Common Stock | CN¥522.40 Million | 39.45% |
| Other Comprehensive Income | CN¥131.33 Million | 9.92% |
| Other Components | CN¥20.36 Million | 1.54% |
| Total Equity | CN¥1.32 Billion | 100.00% |
Jiangxi Sanxin Medtec Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangxi Sanxin Medtec Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jinhe Biotechnology Co Ltd
SHE:002688
|
$438.47 Million |
|
Jiangsu Wuyang Parking Industry Group Co Ltd
SHE:300420
|
$438.70 Million |
|
Xianheng International Science & Technology Co Ltd
SHG:605056
|
$438.74 Million |
|
EVS Broadcast Equipment SA
BR:EVS
|
$438.81 Million |
|
Shibaura Machine Co.Ltd
F:TOA
|
$438.42 Million |
|
Dakota Gold Corp.
NYSE MKT:DC
|
$438.36 Million |
|
Shanghai Aladdin Biochemical Technology Co. Ltd. A
SHG:688179
|
$438.25 Million |
|
Companhia de Saneamento do Paraná - SANEPAR
SA:SAPR3
|
$438.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangxi Sanxin Medtec Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,246,427,038 to 1,324,065,860, a change of 77,638,822 (6.2%).
- Net income of 227,404,091 contributed positively to equity growth.
- Dividend payments of 131,989,411 reduced retained earnings.
- Share repurchases of 43,452,867 reduced equity.
- Other comprehensive income increased equity by 17,748,647.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥227.40 Million | +17.17% |
| Dividends Paid | CN¥131.99 Million | -9.97% |
| Share Repurchases | CN¥43.45 Million | -3.28% |
| Other Comprehensive Income | CN¥17.75 Million | +1.34% |
| Other Changes | CN¥7.93 Million | +0.6% |
| Total Change | CN¥- | 6.23% |
Book Value vs Market Value Analysis
This analysis compares Jiangxi Sanxin Medtec Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 30.81x to 3.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.33 | CN¥10.18 | x |
| 2012-12-31 | CN¥0.41 | CN¥10.18 | x |
| 2013-12-31 | CN¥0.53 | CN¥10.18 | x |
| 2014-12-31 | CN¥0.64 | CN¥10.18 | x |
| 2015-12-31 | CN¥1.06 | CN¥10.18 | x |
| 2016-12-31 | CN¥1.06 | CN¥10.18 | x |
| 2017-12-31 | CN¥1.13 | CN¥10.18 | x |
| 2018-12-31 | CN¥1.15 | CN¥10.18 | x |
| 2019-12-31 | CN¥1.28 | CN¥10.18 | x |
| 2020-12-31 | CN¥1.52 | CN¥10.18 | x |
| 2021-12-31 | CN¥1.76 | CN¥10.18 | x |
| 2022-12-31 | CN¥2.08 | CN¥10.18 | x |
| 2023-12-31 | CN¥2.40 | CN¥10.18 | x |
| 2024-12-31 | CN¥2.59 | CN¥10.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangxi Sanxin Medtec Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.17%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.16%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.68x
- Recent ROE (17.17%) is above the historical average (16.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 28.61% | 15.89% | 1.10x | 1.63x | CN¥22.78 Million |
| 2012 | 30.01% | 17.01% | 1.05x | 1.68x | CN¥31.80 Million |
| 2013 | 23.43% | 15.96% | 0.92x | 1.59x | CN¥27.88 Million |
| 2014 | 19.43% | 15.09% | 0.84x | 1.52x | CN¥23.59 Million |
| 2015 | 9.75% | 16.64% | 0.53x | 1.11x | CN¥-1.31 Million |
| 2016 | 6.63% | 11.52% | 0.51x | 1.13x | CN¥-18.65 Million |
| 2017 | 7.32% | 10.50% | 0.60x | 1.16x | CN¥-15.52 Million |
| 2018 | 6.79% | 7.74% | 0.64x | 1.37x | CN¥-19.46 Million |
| 2019 | 9.22% | 8.55% | 0.63x | 1.71x | CN¥-5.23 Million |
| 2020 | 14.73% | 12.30% | 0.76x | 1.59x | CN¥37.11 Million |
| 2021 | 17.22% | 13.39% | 0.83x | 1.55x | CN¥65.36 Million |
| 2022 | 17.16% | 13.82% | 0.75x | 1.66x | CN¥77.02 Million |
| 2023 | 16.58% | 15.89% | 0.64x | 1.63x | CN¥81.99 Million |
| 2024 | 17.17% | 15.16% | 0.68x | 1.68x | CN¥95.00 Million |
Industry Comparison
This section compares Jiangxi Sanxin Medtec Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,339,628,171
- Average return on equity (ROE) among peers: 11.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangxi Sanxin Medtec Co Ltd (300453) | CN¥1.48 Billion | 28.61% | 0.56x | $438.45 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.03 Billion | -9.26% | 2.64x | $356.80 Million |
| Blue Sail Medical Co Ltd (002382) | $10.54 Billion | 10.97% | 0.61x | $760.18 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $2.33 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $360.97 Million |
| Guangzhou Improve Med Instrument (300030) | $592.55 Million | 4.90% | 0.10x | $242.74 Million |
| Shanghai Tofflon Science Tech (300171) | $2.41 Billion | 11.06% | 0.57x | $802.27 Million |
| Truking Technology Ltd (300358) | $320.32 Million | 29.77% | 1.35x | $556.14 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $1.55 Billion | 13.64% | 0.15x | $1.61 Billion |
| Autek China Inc (300595) | $105.24 Million | 28.59% | 0.10x | $1.21 Billion |